Ardelyx (ARDX) Expected to Post Quarterly Earnings on Tuesday

Key Points

• Ardelyx is expected to report Q3 2026 results after Tuesday’s market close, with analysts forecasting a loss of $0.0148 per share and revenue of $128.66 million. The earnings call is scheduled for 4:30 p.m. ET.
• The company’s previous quarter missed expectations, reporting a $0.07 per-share loss versus the $0.05 consensus estimate, although revenue rose 34.3% year over year to $120.88 million.
• ARDX shares opened at $3.00, near their 52-week low of $2.99, while analysts maintain a “Moderate Buy” consensus and a $13.90 price target. The stock also faces legal and reputational risks from a pending securities class-action lawsuit alleging misleading sales projections.

Ardelyx (NASDAQ:ARDX - Get Free Report) is expected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Ardelyx to announce earnings of ($0.0148) per share and revenue of $128.66 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Ardelyx (NASDAQ:ARDX - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.02). The company had revenue of $120.88 million for the quarter, compared to the consensus estimate of $121.03 million. Ardelyx had a negative return on equity of 36.00% and a negative net margin of 12.35%. Ardelyx's revenue was up 34.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.08) EPS. On average, analysts expect Ardelyx to post ($0.20) EPS for the current fiscal year and $0.24 EPS for the next fiscal year.

Ardelyx Stock Performance

ARDX opened at $3.00 on Tuesday. The company has a debt-to-equity ratio of 1.69, a quick ratio of 3.15 and a current ratio of 3.34. The stock has a market capitalization of $747.56 million, a price-to-earnings ratio of -13.64 and a beta of 0.68. The company has a fifty day moving average of $3.52 and a 200 day moving average of $5.42. Ardelyx has a fifty-two week low of $2.99 and a fifty-two week high of $8.40.

Wall Street Analyst Weigh In

ARDX has been the subject of several research reports. Zacks Research raised shares of Ardelyx from a "strong sell" rating to a "hold" rating in a report on Friday, October 16th. HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of Ardelyx in a research report on Friday, August 7th. BTIG Research reduced their target price on Ardelyx from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Friday, August 7th. TD Cowen reduced their target price on Ardelyx from $13.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, August 7th. Finally, Citigroup decreased their target price on Ardelyx from $14.00 to $11.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Ardelyx presently has a consensus rating of "Moderate Buy" and a consensus price target of $13.90.

Insiders Place Their Bets

In other news, insider Eric Foster sold 8,562 shares of the company's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $33,049.32. Following the sale, the insider directly owned 409,410 shares in the company, valued at approximately $1,580,322.60. This represents a 2.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Raab sold 58,574 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $226,095.64. Following the completion of the transaction, the chief executive officer directly owned 1,619,792 shares of the company's stock, valued at approximately $6,252,397.12. The trade was a 3.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 126,059 shares of company stock worth $486,588. Insiders own 5.30% of the company's stock.

Key Headlines Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Neutral Sentiment: A market-data update reported October short interest of 0 shares and a days-to-cover ratio of 0.0 based on average daily volume. The figure appears inconsistent with the report’s statement that short interest increased, so it provides no clear evidence of meaningful short-selling pressure.
• Negative Sentiment: Multiple law firms, including Robbins LLP, Levi & Korsinsky, Bronstein, Kaplan Fox, Rosen Law Firm and Faruqi & Faruqi, reminded investors about a pending securities class action against Ardelyx. The case covers investors who purchased shares between January 13, 2025, and August 6, 2026, with a November 16, 2026 deadline to seek lead-plaintiff status. Robbins LLP class-action announcement
• Negative Sentiment: The lawsuit alleges that Ardelyx’s chief executive, two successive chief financial officers and chief commercial officer made or controlled misleading statements regarding projected combined peak sales of $1.75 billion for IBSRELA and XPHOZAH, while payer-access barriers were allegedly developing. These are allegations, not proven findings, but the litigation creates legal, financial and reputational risks for the company. Levi & Korsinsky class-action announcement

About Ardelyx

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company's platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx's marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.